Skip to main content
. 2019 Mar 28;11(3):231–244. doi: 10.1093/jmcb/mjz007

Figure 3.

Figure 3

MDM4 is an emerging therapeutic target in cancer. Two primary approaches are to (A) interrupt its engagement of p53 using small molecules and stapled peptides and (B) reduce MDM4 expression levels by interfering with its splicing to force the expression of its unstable isoform MDM-S.